No Data
Spero Therapeutics Presents In Vitro Data At IDWeek 2024 Showing SPR719 Has Low Propensity For Resistance Development In NTM-PD MAC Strains, Highlighting SPR720's Potential For Prolonged Combination Regimens
H.C. Wainwright Maintains Spero Therapeutics(SPRO.US) With Buy Rating, Maintains Target Price $7
Promising Clinical Developments Underpin Buy Rating for Spero Therapeutics
Spero Therapeutics Phase 1 Trial of Lung Disease Treatment Backs Further Assessment
Spero Therapeutics Shares Are Trading Higher After the Company Announced the Publication of Data From Its Phase 1 Clinical Trial, Which Assessed the Intrapulmonary Pharmacokinetics of SPR719.
Spero Therapeutics Publishes SPR720 Phase 1 Lung Exposure Data In Antimicrobial Agents And Chemotherapy